Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.43 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.39 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.38 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.38 |
| ▸ | IDH2 | P48735 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | LCAT | P04180 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | OGA | O60502 | 6/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23335993 | 0.98 | IDH2 (0.48) | IDH2KDM4EABL1LMNALCAT | |
| SCHEMBL21624807 | 0.89 | CAMK1D (0.45) | IDH2KDM4EABL1LMNAKCNH2 | |
| SCHEMBL21624806 | 0.89 | CAMK1D (0.45) | IDH2KDM4EABL1LMNAKCNH2 | |
| SCHEMBL355858 | 0.81 | LCAT (0.48) | IDH2KDM4EABL1LMNALCAT | |
| SCHEMBL12412568 | 0.81 | PTPN11 (0.40) | IDH2GPR119PTPN11 | |
| SCHEMBL26123624 | 0.81 | GPR119 (0.43) | KDM4EABL1LMNALCATCYP3A4 | |
| Hydrochloric Acid SCHEMBL31381926 | 0.81 | LMNA (0.47) | KDM4EABL1LMNAPARP1CHRM2 | |
| SCHEMBL19741318 | 0.81 | HRH4 (0.44) | OGACHRM2 | |
| Hydrochloric Acid SCHEMBL23297102 | 0.80 | OGA (0.41) | LCATCYP3A4OGAGPR119PTPN11 | |
| Hydrochloric Acid SCHEMBL29773190 | 0.80 | KDM4E (0.67) | KDM4EABL1LMNACYP3A4GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | NOVOSTAR PHARMACEUTICALS, LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-07-04 | — | — | US | disclosed |
| CN-115785074-B | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4338737-A1 | PARP7 INHIBITOR AND USE THEREOF | Novostar Pharmaceuticals, Ltd. (CN) | 2024-03-20 | — | — | EP | disclosed |
| EP-4313300-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| US-20240034728-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| CN-117460723-A | Pharmaceutical compounds | 杜克街生物有限公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2023185073-A1 | PARP7 INHIBITOR AND USE THEREOF | 诺沃斯达药业(上海)有限公司 | 2023-10-05 | — | — | WO | disclosed |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | RIBON THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-115785074-A | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2022207752-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2022-10-06 | — | — | WO | disclosed |
| EP-4051384-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114761086-A | Pyridazinones as PARP7 inhibitors | 里邦医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20210130342-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-05-06 | — | — | US | disclosed |
| WO-2021087025-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | F11, F12, ZYX | ABL1 2789/4885PARP1 1174/4885KCNH2 1047/4885 |
| US-20210130342-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | ABL1 1004/4885PARP1 2/4885KCNH2 4240/4885 |
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | PARP1, PARP3, PARP11 | ABL1 2734/4885PARP1 1/4885KCNH2 4748/4885 |
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | PARP3, PARP2, PARP1 | ABL1 3126/4885PARP1 3/4885KCNH2 878/4885 |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | PARP2, PARP1, PARP4 | ABL1 1095/4885PARP1 2/4885KCNH2 3049/4885 |
| US-20240034728-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | ABL1 1004/4885PARP1 2/4885KCNH2 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.